Atara Biotherapeutics (NASDAQ:ATRA) Stock Price Passes Below Fifty Day Moving Average – Here’s What Happened

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) crossed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $5.06 and traded as low as $4.30. Atara Biotherapeutics shares last traded at $4.32, with a volume of 77,139 shares.

Atara Biotherapeutics News Roundup

Here are the key news stories impacting Atara Biotherapeutics this week:

• Positive Sentiment: Recent quarterly results showed an EPS and revenue beat (quarter announced Mar. 16), which provides a fundamental reason for the stock’s intraday strength and may support valuation recovery despite longer?term negative EPS expectations.
• Neutral Sentiment: Technical note — coverage flagged that ATRA recently passed below its 50?day moving average, a short?term bearish signal technical traders watch; this is a mixed/neutral factor versus the earnings beat. Article Title
• Negative Sentiment: Pomerantz LLP announced the filing of a class action against Atara and certain officers (Central District of California), alleging securities law violations for the period May 20, 2024–Jan 9, 2026; litigation naming executives increases headline risk and potential financial exposure. Article Title
• Negative Sentiment: Multiple plaintiff?side firms (Rosen, Levi & Korsinsky, Faruqi & Faruqi, Robbins, Schall, Gross, Schall, Law Offices of Frank R. Cruz, Howard G. Smith, and others) are actively soliciting Atara investors and reminding shareholders of the May 22, 2026 lead?plaintiff deadline — a sign the litigation campaign is broad and likely to keep ATRA in the headlines. Representative notices: Rosen Law Firm. Article Title
• Negative Sentiment: Additional firm notices and recruitment (Levi & Korsinsky, Faruqi & Faruqi, Robbins LLP, etc.) increase the probability of more plaintiffs and potential follow?on claims or settlements, which could pressure the stock and investor sentiment until resolved. Example: Levi & Korsinsky notice. Article Title

Wall Street Analyst Weigh In

ATRA has been the subject of several recent analyst reports. Wall Street Zen downgraded shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. New Street Research set a $6.00 target price on shares of Atara Biotherapeutics in a research report on Tuesday, January 13th. Canaccord Genuity Group reissued a “hold” rating and set a $6.00 target price (down from $25.00) on shares of Atara Biotherapeutics in a research note on Tuesday, January 13th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Atara Biotherapeutics in a research note on Friday, March 27th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Atara Biotherapeutics has an average rating of “Reduce” and a consensus price target of $6.00.

Atara Biotherapeutics Stock Up 9.3%

The stock has a 50 day simple moving average of $5.08 and a 200 day simple moving average of $10.82. The stock has a market cap of $42.29 million, a price-to-earnings ratio of 1.66 and a beta of -0.34.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Monday, March 16th. The biotechnology company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.43. Atara Biotherapeutics had a negative return on equity of 79.12% and a net margin of 27.07%.The company had revenue of $1.60 million for the quarter, compared to analyst estimates of $0.70 million. Equities analysts expect that Atara Biotherapeutics, Inc. will post -10.39 earnings per share for the current year.

Insiders Place Their Bets

In other Atara Biotherapeutics news, major shareholder Innovation Ltd Panacea sold 80,554 shares of the firm’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $6.07, for a total value of $488,962.78. Following the transaction, the insider directly owned 1,324,446 shares of the company’s stock, valued at approximately $8,039,387.22. This trade represents a 5.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 4.00% of the company’s stock.

Institutional Investors Weigh In On Atara Biotherapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Raymond James Financial Inc. bought a new stake in Atara Biotherapeutics during the second quarter worth $31,000. Dimensional Fund Advisors LP purchased a new position in Atara Biotherapeutics during the 4th quarter worth $181,000. Walleye Capital LLC purchased a new position in Atara Biotherapeutics during the 4th quarter worth $220,000. Marshall Wace LLP bought a new stake in shares of Atara Biotherapeutics in the 2nd quarter worth $327,000. Finally, Quadrature Capital Ltd grew its stake in shares of Atara Biotherapeutics by 22.8% in the 4th quarter. Quadrature Capital Ltd now owns 20,321 shares of the biotechnology company’s stock worth $368,000 after acquiring an additional 3,779 shares in the last quarter. 70.90% of the stock is owned by institutional investors.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders.

The company’s lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers.